Incyte Corporation - Common Stock (NQ:INCY)

115.30 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

29 30 Next >

Incyte Named One of Top 5 Companies on Science Magazine’s 2024 Top Employers List

October 24, 2024

From Incyte

Via Business Wire

Peeling Back The Layers: Exploring Incyte Through Analyst Insights ↗

October 23, 2024

Via Benzinga

Uncovering Noteworthy Technical Analysis Findings for INCYTE CORP (NASDAQ:INCY). ↗

October 14, 2024

NASDAQ:INCY may be ready to breakout.

Via Chartmill

A Look Into Incyte Inc's Price Over Earnings ↗

October 10, 2024

Via Benzinga

Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program

October 10, 2024

From Incyte

Via Business Wire

Assessing Incyte: Insights From 11 Financial Analysts ↗

October 01, 2024

Via Benzinga

Incyte Stock: A Deep Dive Into Analyst Perspectives (9 Ratings) ↗

September 03, 2024

Via Benzinga

Incyte to Report Third Quarter Financial Results

October 08, 2024

From Incyte

Via Business Wire

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 07, 2024

From Incyte

Via Business Wire

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2024

From Incyte

Via Business Wire

Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate ↗

September 30, 2024

Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC...

Via Benzinga

Analyst Expectations For Incyte's Future ↗

August 15, 2024

Via Benzinga

Analyst Ratings For Incyte ↗

July 26, 2024

Via Benzinga

Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress

September 25, 2024

From Incyte

Via Business Wire

Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets ↗

September 18, 2024

Truist Securities has downgraded Incyte due to concerns over Jakafi's patent expiration in 2028. Jakafi, Incyte's top-selling drug, faces potential revenue decline amid generic competition. Truist...

Via Benzinga

Topics Intellectual Property

Wall Street Lower Ahead Of Interest Rate Move ↗

September 18, 2024

Stocks are slightly lower this afternoon, as investors hope for the Federal Open Market Committee (FOMC) to issue its first interest rate cut in four years later today.

Via Talk Markets

Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers ↗

September 16, 2024

Intel kept running late on yet another big deal.

Via Investor's Business Daily

Topics Stocks

Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

September 14, 2024

From Incyte

Via Business Wire

Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium

September 14, 2024

From Incyte

Via Business Wire

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 09, 2024

From Incyte

Via Business Wire

Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024

August 21, 2024

From Incyte

Via Business Wire

Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study ↗

August 16, 2024

Incyte's Phase 3 inMIND trial of Monjuvi (tafasitamab) combined with lenalidomide and rituximab meets primary endpoints in relapsed follicular lymphoma patients, showing positive progression-free...

Via Benzinga

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

August 15, 2024

From Incyte

Via Business Wire

FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication ↗

August 15, 2024

The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at least two prior therapies, providing new hope for those with this serious...

Via Benzinga

Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

August 14, 2024

From Incyte and Syndax Pharmaceuticals

Via Business Wire

Incyte to Present at Upcoming Investor Conferences

August 13, 2024

From Incyte

Via Business Wire

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 07, 2024

From Incyte

Via Business Wire

After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial ↗

July 31, 2024

MacroGenics will discontinue vobra duo for remaining mCRPC participants after five deaths. New data to be presented at ESMO 2024 conference.

Via Benzinga

Topics Death

Incyte's Q2 Earnings: Wider Than Expected Loss, Pipeline Review, Lifts Jakafi Sales Guidance ↗

July 30, 2024

Incyte reported Q2 revenue of $1.04 billion, beating consensus, with Jakafi revenue at $705.9 million and Opzelura revenue up 52%. Despite an adjusted EPS loss, the company updated its 2024 Jakafi...

Via Benzinga

Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

July 30, 2024

From Incyte

Via Business Wire

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.